Management of age-related osteoporosis and prevention of associated fractures

Therapeutics and Clinical Risk Management

Volumn 2, Issue 3, 2006, Pages 281-295

  MacLaughlin, Eric J ^a   Sleeper, Rebecca B ^b   McNatty, Danny ^b   Raehl, Cynthia L ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Fracture; Osteoporosis; Prevention; Treatment

Indexed keywords

ALENDRONIC ACID; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCITRIOL; CALCIUM; CALCIUM CARBONATE; CARDIOVASCULAR AGENT; ESTROGEN; FLUORIDE SODIUM; GESTAGEN; GLUCOCORTICOID; HEPARIN; IBANDRONIC ACID; IMMUNOSUPPRESSIVE AGENT; NEUROLEPTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; PROGESTERONE; RALOXIFENE; RISEDRONIC ACID; SALCATONIN; SELECTIVE ESTROGEN RECEPTOR MODULATOR; STRONTIUM RANELATE; THYROID HORMONE; TIBOLONE; UNINDEXED DRUG; VITAMIN D;

ATAXIA; BLURRED VISION; BONE FRAGILITY; BREAST CANCER; BREAST TENDERNESS; CALCIUM BLOOD LEVEL; CALCIUM URINE LEVEL; CHOLECYSTITIS; CLINICAL TRIAL; COGNITIVE DEFECT; COMORBIDITY; CORTICOSTEROID INDUCED OSTEOPOROSIS; COST OF ILLNESS; DEEP VEIN THROMBOSIS; DELIRIUM; DIABETES MELLITUS; DISEASE CLASSIFICATION; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG INTERMITTENT THERAPY; DRUG MECHANISM; DUAL ENERGY X RAY ABSORPTIOMETRY; ELDERLY CARE; ENDOMETRIUM CANCER; EXTRAPYRAMIDAL SYMPTOM; FALL RISK; FALLING; FRAGILITY FRACTURE; GASTROINTESTINAL SYMPTOM; GERIATRIC PATIENT; HEART ARRHYTHMIA; HIP FRACTURE; HORMONE SUBSTITUTION; HUMAN; HYPERCALCEMIA; HYPOGLYCEMIA; ISCHEMIC HEART DISEASE; LUNG EMBOLISM; NEPHROLITHIASIS; NONHUMAN; ORTHOSTATIC HYPOTENSION; OSTEOLYSIS; OSTEOPENIA; PAGET BONE DISEASE; PARATHYROID HORMONE BLOOD LEVEL; POSTMENOPAUSE OSTEOPOROSIS; PSYCHOMOTOR DISORDER; RECURRENCE RISK; RESTLESSNESS; REVIEW; RISK ASSESSMENT; RISK FACTOR; SEDATION; SENILE OSTEOPOROSIS; SEX DIFFERENCE; SIDE EFFECT; STROKE; VAGINA BLEEDING; VENOUS THROMBOEMBOLISM; VERTEBRA FRACTURE; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY;

EID: 33748453010     PISSN: 11766336     EISSN: None     Source Type: Journal    
DOI: 10.2147/tcrm.2006.2.3.281     Document Type: Review

References (116)

1. Aaron JE, Gallagher JC, Anderson J, et a]. 1974. Frequency of osteomalacia and osteoporosis in fractures of the proximal femur. Lancet, 1:229-33.
2. Adams JS, Kantorovich V, Wu C, et al. 1999. Resolution of vitamin D insufficiency in osteopenic patients results in rapid recovery of bone mineral density. J Clin Endocrinol Metab, 84:2729-30.
3. Amin S, Felson DT. 2001. Osteoporosis in men. Rheum Dis Clin North Am, 27:19-47.
4. Bischoff-Ferrari HA, Dietrich T, Orav EJ, et al. 2004. Positive association between 25-hydroxy vitamin D levels and bone mineral density: a population-based study of younger and older adults. Am J Med, 116:634-9.
5. Bischoff-Ferrari HA, Willett WC, Wong JB, et al. 2005. Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. JAMA, 293:2257-64.
6. Black DM, Bilezikian JP, Ensrud KE, et al. 2005. One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. N Engl J Med, 353:555-65.
7. Black DM, Greenspan SL, Ensrud KE, et al. 2003. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med, 349:1207-15.
8. Black DM, Thompson DE, Bauer DC, et al. 2000. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab, 85:4118-24.
9. Bone HG, Greenspan SL, McKeever C, et al. 2000. Alendronate and estrogen effects in postmenopausal women with low bone mineral density. J Clin Endocrinol Metab, 85:720-6.
10. Brown JP, Kendler DL, McClung MR, ct al. 2002. The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int, 71:103-11.
11. Cadarette SM, Jaglal SB, Kreiger N, et al. 2000. Development and validation of the Osteoporosis Risk Assessment Instrument to facilitate selection of women for bone densitometry. CMAJ, 162:1289-94.
12. Cauley JA, Black DM, Barrett-Connor E, et al. 2001. Effects of hormone replacement therapy on clinical fractures and height loss: The Heart and Estrogen/Progestin Replacement Study (HERS). Am J Med, 110:442-50.
13. Cauley JA, Norton L, Lippman ME, et al. 2001. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat, 65:125-34.
14. Cauley JA, Robbins J, Chen Z, et al. 2003. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. JAMA, 290:1729-38.
15. Center JR, Nguyen TV, Schneider D, et al. 1999. Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet, 353:878-82.
16. Chapuy MC, Arlot ME, Duboeuf F, et al. 1992. Vitamin D3 and calcium to prevent hip fractures in the elderly women. N Engl J Med, 327:1637-42.
17. Chesnut CH 3rd, Silverman S, Andriano K, et al. 2000. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med, 109:267-76.
18. Chesnut IC, Skag A, Christiansen C, et al. 2004. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res, 19:1241-9.
19. Compston JE, Papapoulos SE, Blanchard F. 1998. Report on osteoporosis in the European Community: current status and recommendations for the future. Working Party from European Union Member States. Osteoporos Int, 8:531-4.
20. Cramer JA, Amonkar MM, Hebborn A, et al. 2005. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin, 21:1453-60.
21. Cumming RG. 1998. Epidemiology of medication-related falls and fractures in the elderly. Drugs Aging, 12:43-53.
22. Cummings SR, Bates D, Black DM. 2002. Clinical use of bone densitometry: scientific review. JAMA, 288:1889-97.
23. Cummings SR, Black DM, Nevitt MC, et al. 1993. Bone density at various sites for prediction of hip fractures. The Study of Osteoporotic Fractures Research Group. Lancet, 341:72-5.
24. Cummings SR, Black DM, Thompson DE, et al. 1998. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA, 280:2077-82.
25. Dawson-Hughes B, Harris SS, Krall EA, et al. 1997. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med, 337:670-6.
26. Delmas PD, Bjarnason NH, Mitlak BH, et al. 1997. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med, 337:1641-7.
27. Dolan P, Torgerson DJ. 1998. The cost of treating osteoporotic fractures in the United Kingdom female population. Osteoporos Int, 8:611-17.
28. Elliott ME, Drinka PJ, Krause P, et al. 2004. Osteoporosis assessment strategies for mate nursing home residents. Maturitas, 49:225-33.
29. Empana JP, Dargent-Molina P, Breart G. 2004. Effect of hip fracture on mortality in elderly women: the EPIDOS prospective study. J Am Geriatr Soc, 52:685-90.
30. Ettinger B, Black DM, Midak BH, et al. 1999. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA, 282:637-45.
31. Ettinger B, Ensrud KE, Wallace R, et al. 2004. Effects of ultralow-dose transdermal estradiol on bone mineral density: a randomized clinical trial. Obstet Gynecol, 104:443-51.
32. Farley JR, Wergedal JE, Baylink DJ. 1983. Fluoride directly stimulates proliferation and alkaline phosphatase activity of bone-forming cells. Science, 222:330-2.
33. Fink HA, Ensrud KE, Nelson DB, et al. 2003. Disability after clinical fracture in postmenopausal women with low bone density: the fracture intervention trial (FIT). Osteoporos Int, 14:69-76.
34. Finkelstein JS, Hayes A, Hunzelman JL, et al. 2003. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med, 349:1216-26.
35. Gallagher JC, Goldgar D. 1990. Treatment of postmenopausal osteoporosis with high doses of synthetic calcitriol. A randomized controlled study. Ann Intern Med, 113:649-55.
36. Grady D, Gebretsadik T, Kerlikowske K, et al. 1995. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol, 85:304-13.
37. Granek E, Baker SP, Abbey H, et al. 1987. Medications and diagnoses in relation to falls in a long-term care facility. J Am Geriatr Soc, 35:503-11.
38. Grant AM, Avenell A, Campbell MK, et al. 2005. Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD): a randomised placebo-controlled trial. Lancet, 365:1621-8.
39. Greenspan SL, Resnick NM, Parker RA. 2003. Combination therapy with hormone replacement and alendronate for prevention of bone loss in elderly women: a randomized controlled trial. JAMA, 289:2525-33.
40. Gruber HE, Ivey JL, Baylink DJ, et al. 1984. Long-term calcitonin therapy in postmenopausal osteoporosis. Metabolism, 33:295-303.
41. Hallberg I, Rosenqvist AM, Kartous L, et al. 2004. Health-related quality of life after osteoporotic fractures. Osteoporos Int, 15:834-41.
42. Harris ST, Eriksen EF, Davidson M, et al. 2001. Effect of combined risedronate and hormone replacement therapies on bone mineral density in postmenopausal women. J Clin Endocrinol Metab, 86:1890-7.
43. Harris ST, Watts NB, Genant HK, et al. 1999. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA, 282:1344-52.
44. Hodsman AB, Bauer DC, Dempster D, et al. 2005. Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev, 26:688-703.
45. Holick MF, Siris ES, Binkley N, et al. 2005. Prevalence of vitamin D inadequacy among postmenopausal North American women receiving osteoporosis therapy. J Clin Endocrinol Metab, 90:3215-24.
46. Hulley S, Grady D, Bush T, et al. 1998. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA, 280:605-13.
47. Jackson RD, LaCroix AZ, Gass M, et al. 2006. Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med, 354:669-83.
48. Johnell O, Kanis JA. 2004. An estimate of the worldwide prevalence, mortality and disability associated with hip fracture. Osteoporos Int, 15:897-902.
49. Johnell O, Scheele WH, Lu Y, et al. 2002. Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis. J Clin Endocrinol Metab, 87:985-92.
50. Kamel HK. 2004. Underutilization of calcium and vitamin D supplements in an academic long-term care facility. J Am Med Dir Assoc, 5:98-100.
51. Kanis JA, Gluer CC. 2000. An update on the diagnosis and assessment of osteoporosis with densitometry. Committee of Scientific Advisors, International Osteoporosis Foundation. Osteoporos Int, 11:192-202.
52. Kannus P, Sievanen H, Palvanen M, et al. 2005. Prevention of falls and consequent injuries in elderly people. Lancet, 366:1885-93.
53. [Lasofoxifenel 2005. Lasofoxifene: CP 336156, CP-336156. Drugs R D, 6:56-60.
54. LeBoff MS, Kohlmeier L, Hurwitz S, et al. 1999. Occult vitamin D deficiency in postmenopausal US women with acute hip fracture. JAMA, 281:1505-11.
55. Lewiecki EM, Watts NB, McClung MR, et al. 2004. Official positions of the international society for clinical densitometry. J Clin Endocrinol Metab, 89:3651-5.
56. Licata AA. 2005. Discovery, clinical development, and therapeutic uses of bisphosphonates. Ann Pharmacother, 39:668-77.
57. Lindsay R, Gallagher JC, Kleerekoper M, et al. 2002. Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women. JAMA, 287:2668-76.
58. Lips P, Cooper C, Agnusdei D, et al. 1999. Quality of life in patients with vertebral fractures: validation of the Quality of Life Questionnaire of the European Foundation for Osteoporosis (QUALEFFO). Working Party for Quality of Life of the European Foundation for Osteoporosis. Osteoporos Int, 10: 150-60.
59. Lips P, Graafmans WC, Ooms ME, et al. 1996. Vitamin D supplementation and fracture incidence in elderly persons. A randomized, placebo-controlled clinical trial. Ann Intern Med, 124:400-6.
60. Lydick E, Cook K, Turpin J, et al. 1998. Development and validation of a simple questionnaire to facilitate identification of women likely to have low bone density. Am J Manag Care, 4:37-48.
61. Lyritis GP, Tsakalakos N, Magiasis B, et al. 1991. Analgesic effect of salmon calcitonin in osteoporotic vertebral fractures: a double-blind placebo-controlled clinical study. Calcif Tissue Int, 49:369-72.
62. Malabanan A, Veronikis IE, Holick MF. 1998. Redefining vitamin D insufficiency. Lancet, 351:805-6.
63. Margolis DJ, Knauss J, Bilker W, et al. 2003. Medical conditions as risk factors for pressure ulcers in an outpatient setting. Age Ageing, 32:259-64.
64. Marie PJ. 2005. Strontium as therapy for osteoporosis. Curr Opin Pharmacol, 5:633-6.
65. Marshall D, Johnell O, Wedel H. 1996. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ, 312:1254-9.
66. Martino S, Disch D, Dowsett SA, et al. 2005. Safety assessment of raloxifene over eight years in a clinical trial setting. Curr Med Res Opin, 21:1441-52.
67. McClung MR, Geusens P, Miller PD, et al. 2001. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med, 344:333-40.
68. Meunier PJ, Roux C, Seeman E, et al. 2004. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med, 350:459-68.
69. Meunier PJ, Slosman DO, Delmas PD, et al. 2002. Strontium ranelate: dose-dependent effects in established postmenopausal vertebral osteoporosis - a 2-year randomized placebo controlled trial. J Clin Endocrinol Metab, 87:2060-6.
70. Miller PD, McClung MR, Macovei L, et al. 2005. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res, 20:1315-22.
71. [NAS] National Academy of Sciences. Institute of Medicine, Food, and Nutrition Board. 1997. Dietary reference intake tables: vitamins [online]. Accessed on 22 December 2005. URL: http://www.iom.edu/ Object.File/Master/7/296/0.pdf.
72. Need AG, O'Loughlin PD, Morris HA, et al. 2004. The effects of age and other variables on serum parathyroid hormone in postmenopausal women attending an osteoporosis center. J Clin Endocrinol Metab, 89:1646-9.
73. Neer RM, Arnaud CD, Zanchetta JR, et al. 2001. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med, 344:1434-41.
74. Nevitt MC, Ettinger B, Black DM, et al. 1998. The association of radiographically detected vertebral fractures with back pain and function: a prospective study. Ann Intern Med, 128:793-800.
75. [NIH] NIH Consensus conference. 1994. Optimal calcium intake. NIH Consensus Development Panel on Optimal Calcium Intake. JAMA, 272:1942-8.
76. [NIH] NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. 2001. Osteoporosis prevention, diagnosis, and therapy. JAMA, 285:785-95.
77. [NOF] National Osteoporosis Foundation. 2004. Physician's guide to prevention and treatment of osteoporosis [online]. Accessed on 23 March 2005. URL: http://www.nof.org/physguide/index.htm.
78. [NOF] National Osteoporosis Foundation. 2005a. America's bone health: the state of osteoporosis and low bone mass [online], Accessed on 16 November 2005. URL: http://www.nof.org/advocacy/prcvalence/index.htm.
79. [NOF] National Osteoporosis Foundation. 2005b. Osteoporosis: fast facts [online]. Accessed on 15 November 2005. URL: http://www.nof.org/ osteoporosis/diseasefacts.htm.
80. Notelovitz M. 1997. Estrogen therapy and osteoporosis: principles & practice. Am J Med Sci, 313:2-12.
81. Orwoll E, Ettinger M, Weiss S, et al. 2000. Alendronate for the treatment of osteoporosis in men. N Engl J Med, 343:604-10.
82. Orwoll ES, Scheele WH, Paul S, et al. 2003. The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res, 18:9-17.
83. Pavlov PW, Ginsburg J, Kicovic PM, et al. 1999. Double-blind, placebo-controlled study of the effects of tibolone on bone mineral density in postmenopausal osteoporotic women with and without previous fractures. Gynecol Endocrinol, 13:230-7.
84. Reginster J, Minne HW, Sorensen OH, et al. 2000. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int, 11:83-91.
85. Reginster JY, Gillet P, Ben Sedrine W, et al. 1999. Direct costs of hip fractures in patients over 60 years of age in Belgium. Pharmacoeconomics, 15:507-14.
86. Reginster TY, Sarlet N, Lejeune E, et al. 2005. Strontium ranelate: a new treatment for postmenopausal osteoporosis with a dual mode of action. Curr Osteoporos Rep, 3:30-4.
87. Reginster JY, Seeman E, De Vernejoul. MC, et al. 2005. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) Study. J Clin Endocrinol Metab, 90:2816-22.
88. Riggs BL, Hartmann LC. 2003. Selective estrogen-receptor modulators - mechanisms of action and application to clinical practice. N Engl J Med, 348:618-29.
89. Riggs BL, Hodgson SF, O'Fallon WM, et al. 1990. Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Engl J Med, 322:802-9.
90. Rizzoli R, Greenspan SL, Bone G 3rd, et al. 2002. Two-year results of once-weekly administration of alendronate 70mg for the treatment of postmenopausal osteoporosis. J Bone Miner Res, 17:1988-96.
91. Ronkin S, Northington R, Baracat E, et al. 2005. Endometrial effects of bazedoxifene acetate, a novel selective estrogen receptor modulator, in postmenopausal women. Obstet Gynecol, 105:1397-404.
92. Roux C, Pelissier C, Fechtenbaum J, et al. 2002. Randomized, double-masked, 2-year comparison of tibolone with 17beta-estradiol and norethindrone acetate in preventing postmenopausal bone loss. Osteoporos Int, 13:241-8.
93. Rubin CD, Pak CY, Adams-Huet B, et al. 2001. Sustained-release sodium fluoride in the treatment of the elderly with established osteoporosis. Arch Intern Med, 161:2325-33.
94. Rubin MR, Bilezikian JP. 2003. New anabolic therapies in osteoporosis. Endocrinol Metab Clin North Am, 32:285-307.
95. Rymer J, Robinson J, Fogelman I. 2001. Effects of 8 years of treatment with tibolone 2.5mg daily on postmenopausal bone loss. Osteoporos Int, 12:478-83.
96. Schlaich C, Minne HW, Bruckner T, et al. 1998. Reduced pulmonary function in patients with spinal osteoporotic fractures. Osteoporos Int, 8:261-7.
97. Selby P. 2004. Postmenopausal osteoporosis. Curr Osteoporos Rep, 2: 101-6.
98. Shea B, Wells G, Cranney A, et al. 2002. Meta-analyses of therapies for postmenopausal osteoporosis. VII. Meta-analysis of calcium supplementation for die prevention of postmenopausal osteoporosis. Endocr Rev, 23:552-9.
99. Sleeper RB, Bond C, Rojas-Fernandez C. 2000. Psychotropic drugs and falls: New evidence pertaining to SSRI's. Pharmacotheraphy, 20:308-17.
100. [Teriparatide] 2003. Teriparatide (forteo) for osteoporosis. Med Lett Drugs Ther, 45:9-10.
101. Thiebaud D, Bigler JM, Renteria S, et al. 1998. A 3-year study of prevention of postmenopausal bone loss: conjugated equine estrogens plus medroxyprogesterone acetate versus tibolone. Climacteric, 1:202-10.
102. Tilyard MW, Spears GF, Thomson J, et al. 1992. Treatment of postmenopausal osteoporosis with calcitriol or calcium. N Engl J Med, 326:357-62.
103. Tinetti ME, Williams CS. 1997. Falls, injuries due to falls, and the risk of admission to a nursing home. N Engl J Med, 337:1279-84.
104. Torgerson DJ, Bell-Syer SE. 2001a. Hormone replacement therapy and prevention of nonvertebral fractures: a meta-analysis of randomized trials. JAMA, 285:2891-7.
105. Torgerson DJ, Bell-Syer SE. 2001b. Hormone replacement therapy and prevention of vertebral fractures: a meta-analysis of randomised trials. BMC Musculoskelet Disord, 2:7.
106. Tucci JR. 2006. Importance of early diagnosis and treatment of osteoporosis to prevent fractures. Am J Manag Care, 12:S181-90.
107. [USPSTF] US Preventive Services Task Force. 2005. Hormone therapy for the prevention of chronic conditions in postmenopausal women: recommendations from the US Preventive Services Task Force. Ann Intern Med, 142:855-60.
108. van Weel C, Vermeulen H, van den Bosch W. 1995. Falls, a community care perspective. Lancet, 345:1549-51.
109. Wallach J. 1986. Interpretation of diagnostic tests. A synopsis of laboratory medicine. Boston, MA: Little, Brown & Co.
110. Wells G, Tugwell P, Shea B, et al. 2002. Meta-analyses of therapies for postmenopausal osteoporosis. V. Meta-analysis of the efficacy of hormone replacement therapy in treating and preventing osteoporosis in postmenopausal women. Endocr Rev, 23:529-39.
111. [WGWHII] Writing Group for the Women's Health Initiative Investigators. 2002. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative Randomized Controlled Trial. JAMA, 288:321-33.
112. [WHISC] Women's Health Initiative Steering Committee. 2004. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: The Women's Health Initiative Randomized Controlled Trial. JAMA, 291:1701-12.
113. Wickersham RM, Novak KK, (eds). 2002. Nutrients and nutritional agents. In: Drug facts and comparisons. St. Louis, MO: Wolters Kluwer Health, Inc., p 26-7.
114. Wurz GT, Read KC, Marchisano-Karpman C, et al. 2005. Ospemifene inhibits the growth of dimethylbenzanthracene-induced mammary tumors in Sencar mice. J Steroid Biochem Mol Biol, 97:230-40.
115. Zaidi M, Moonga BS, Abe E. 2002. Calcitonin and bone formation: a knockout full of surprises. J Clin Invest, 110: 1769-71.
116. Zimmerman SI, Girman CJ, Buie VC, et al. 1999. The prevalence of osteoporosis in nursing home residents. Osteoporos Int, 9:151-7.